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Abstract: Purpose Delayed intensification (DI) is an integral part of treatment of childhood acute lym-
phoblastic leukemia (ALL), but it is associated with relevant toxicity. Therefore, standard-risk patients of
trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young
Patients With ALL) were investigated with the specific aim to reduce treatment intensity. Patients and
Methods Between July 2000 and July 2006, 1,164 patients (1 to 17 years of age) with standard-risk ALL
(defined as the absence of high-risk cytogenetics and undetectable minimal residual disease on days 33
and 78) were randomly assigned to either experimental reduced-intensity DI (protocol III; P-III) or stan-
dard DI (protocol II; P-II). Cumulative drug doses of P-III were reduced by 30% for dexamethasone and
50% for vincristine, doxorubicin, and cyclophosphamide, which shortened the treatment duration from
49 to 29 days. The study aimed at noninferiority of reduced-intensity P-III; analyses were performed
according to treatment given. Results For P-III and P-II, respectively, the 8-year rate of disease-free
survival (± SE) was 89.2 ± 1.3% and 92.3 ± 1.2% ( P = .04); cumulative incidence of relapse, 8.7 ±
1.2% and 6.4 ± 1.1% ( P = .09); and overall survival, 96.1 ± 0.8% and 98.0 ± 0.6% ( P = .06). Patients
with ETV6-RUNX1-positive ALL and patients 1 to 6 years of age performed equally well in both arms.
The incidence of death during remission was comparable, which indicates equivalent toxicity. The 8-year
cumulative incidence rate of secondary malignancies was 1.3 ± 0.5% and 0.6 ± 0.4% for P-III and P-II,
respectively ( P = .37). Conclusion Although the criteria used for the standard-risk definition in this
trial identified patients with exceptionally good prognosis, reduction of chemotherapy was not successful
mainly because of an increased rate of relapse. The data suggest that treatment reduction is feasible
in specific subgroups, which underlines the biologic heterogeneity of this cohort selected according to
treatment response.
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A B S T R A C T
Purpose
Delayed intensiﬁcation (DI) is an integral part of treatment of childhood acute lymphoblastic leu-
kemia (ALL), but it is associated with relevant toxicity. Therefore, standard-risk patients of trial
AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young
Patients With ALL) were investigated with the speciﬁc aim to reduce treatment intensity.
Patients and Methods
Between July 2000 and July 2006, 1,164 patients (1 to 17 years of age) with standard-risk ALL
(deﬁned as the absence of high-risk cytogenetics and undetectableminimal residual disease on days
33 and 78) were randomly assigned to either experimental reduced-intensity DI (protocol III; P-III) or
standard DI (protocol II; P-II). Cumulative drug doses of P-III were reduced by 30% for dexa-
methasone and 50% for vincristine, doxorubicin, and cyclophosphamide, which shortened the
treatment duration from 49 to 29 days. The study aimed at noninferiority of reduced-intensity P-III;
analyses were performed according to treatment given.
Results
For P-III and P-II, respectively, the 8-year rate of disease-free survival (6 SE) was 89.2 6 1.3% and
92.3 6 1.2% (P = .04); cumulative incidence of relapse, 8.7 6 1.2% and 6.4 6 1.1% (P = .09); and
overall survival, 96.1 6 0.8% and 98.0 6 0.6% (P = .06). Patients with ETV6-RUNX1–positive ALL
and patients 1 to 6 years of age performed equally well in both arms. The incidence of death during
remissionwas comparable, which indicates equivalent toxicity. The 8-year cumulative incidence rate
of secondary malignancies was 1.3 6 0.5% and 0.6 6 0.4% for P-III and P-II, respectively (P = .37).
Conclusion
Although the criteria used for the standard-risk deﬁnition in this trial identiﬁed patients with excep-
tionally good prognosis, reduction of chemotherapy was not successful mainly because of an in-
creased rate of relapse. The data suggest that treatment reduction is feasible in speciﬁc subgroups,
which underlines the biologic heterogeneity of this cohort selected according to treatment response.
J Clin Oncol 36:244-253. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Over the past decades, the prognosis for children
and adolescents with acute lymphoblastic leukemia
(ALL) has improved considerably. Advances
were mainly accomplished through reﬁnement
of biologic characterization, risk group assignment,
and risk-stratiﬁed treatment.1-4 The assessment of
minimal residual disease (MRD) has introduced
unsurpassed precision in the differentiation
between patients with a high risk of relapse and
those with a low risk.5-7 Prospectively developed in
the 1990s, MRD measured by immunoglobulin/
T-cell receptor gene rearrangement polymerase
chain reaction (PCR-MRD) was implemented for
risk stratiﬁcation in the trial, Combination Che-
motherapy Based on Risk of Relapse in Treating
Young Patients with Acute Lymphoblastic Leuke-
mia (AIEOP-BFM ALL 2000).2,3,6
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With increasing survival rates, therapy-related morbidity and
mortality as well as long-term sequelae have increasingly moved
into focus.8,9 Especially for patient groups with the most favorable
prognosis, several leukemia study groups have strived for a re-
duction of treatment burden without jeopardizing outcome.10-14
In former trials, the ALL–Berlin-Frankfurt-Mu¨nster (BFM)
study group demonstrated the importance of delayed in-
tensiﬁcation in the treatment of patients with low-risk ALL. The
reintensiﬁcation element protocol II (P-II) signiﬁcantly improved
the outcome of high-risk patients in ALL-BFM 76.15 The rein-
tensiﬁcation element (protocol III [P-III]) also was implemented
for low-risk patients in ALL-BFM 79.16,17 ALL-BFM 83 focused
again on reduction of treatment burden in low-risk patients by
testing treatment with and without P-III, which yielded results in
favor of reinduction (10-year probable event-free survival [pEFS]
rate, 81 6 5% v 56 6 6%).16,18
In the era of improved risk assignment, the question of the
adequate chemotherapeutic intensity needed to ensure consistently
low relapse rates was again addressed in a cooperative prospective
trial jointly conducted by two large leukemia study groups—
Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
and Berlin-Frankfurt-Mu¨nster (BFM)—in AIEOP-BFM ALL 2000.
The randomized trial compared standard delayed intensiﬁcation
(P-II) with a reduced-intensity regimen (P-III) in a cohort of standard-
risk (SR) patients with favorable treatment response deﬁned by PCR-
MRD. Herein, we report the results of this trial.
PATIENTS AND METHODS
Study Design
Patients 1 to 17 years of age with ALL in one of the participating
centers in Italy, Germany, Austria, and Switzerland were registered in the
Extra-
Compartment
Delayed Intensification
Reduced DI: P-III
Standard DI: P-II
Maintenance
(until 104 weeks since initial diagnosis)
pCRT for selected indication
Induction
Protocol IA-PDN
Protocol IA-DXM
ConsolidationR
MRD Time Points
Day 33 Day 78
R
Fig 1. Treatment outline of the standard-risk arm of the study AIEOP-BFM ALL 2000. DI, delayed intensiﬁcation; DXM, dexamethasone; MRD, minimal residual disease;
pCRT, preventive cranial radiotherapy; Protocol IA-DXM, protocol I-A (induction regimen) with dexamethasone; Protocol IA-PDN, protocol I-A with prednisone; P-II, protocol
II; P-III, protocol III; R, randomization.
Patients registered 
(N = 4,937)
Not eligible for study
   Significant pretreatment
   ALL was a secondary neoplasm
   Major medical ailment that prevented 
      protocol therapy
   Lack of essential data for establishing 
      the diagnosis
   Treatment or start of treatment in a 
     different protocol
   Other reasons
 (n = 98)
 (n = 48)
 (n = 12)
 (n = 5)
 (n = 18)
 (n = 8)
Not randomly assigned (main reason was parent refusal)
(n = 182)
Eligible for study 
(n = 4,839)
Eligible for random assignment 
(n = 1,346)
Randomly assigned 
(n = 1,164)
Assigned to P-III
   Treated in P-III
   Treated in P-II
Assigned to P-II
  Treated in P-II
  Treated in P-III
  Switch to nonprotocol-
    conforming treatment
 (n = 7)
 (n = 3,429)
(n = 64)
 (n = 583)  (n = 581)
 (n = 562)
  (n = 19)
 (n = 560)
 (n = 22)
  (n = 1)
MR/HR
SR not eligible for random assignment 
  (early event,registration after stop of 
  randomization)
Fig 2. CONSORT diagram. Patient character-
istics of randomly assigned and eligible non-
randomly assigned patients are listed in the Data
Supplement. ALL, acute lymphoblastic leukemia;
HR, high risk; MR, medium risk; P-II, protocol II;
P-III, protocol III; SR, standard risk.
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AIEOP-BFM ALL 2000 trial after written informed consent from their
guardians. Routine initial diagnostics were cytology, immunophenotyping,
and molecular genetic screening for the presence of ETV6-RUNX1, BCR-
ABL1, and KMT2A-AFF1 (MLL-AF4) fusion transcripts. Response assess-
ment was performed by early cytologic assessment as well as by PCR-MRD
on the basis of immunoglobulin and T-cell receptor gene rearrangements..
The respective standard procedures have been published previously.2,3,7,18-21
Good response or poor response to a 7-day prednisone prephase plus
one intrathecal dose of methotrexate were deﬁned as , 1.0 3 109/L and
$ 1.03 109/L blasts in peripheral blood, respectively. Complete remission
(CR) was deﬁned as, 5% blasts in regenerating bonemarrow at the end of
induction treatment and the absence of extramedullary disease. Relapse
was deﬁned as either recurrence of $ 25% lymphoblasts in bone marrow
or localized leukemic inﬁltrate at any site after having achieved CR.
Risk group assignment to the high-risk group in AIEOP-BFM ALL
2000 was based on genetic characterization of ALL (presence of BCR-ABL1,
KMT2A-AFF1) and slow cytologic and molecular response to treatment
(prednisone poor response, no CR on day 33, or MRD$ 53 1024 on day
78). In the absence of the aforementioned high-risk criteria, patients were
assigned to the SR group if MRD was negative on days 33 and 78 with at
least two markers with a sensitivity of 1 3 1024. The remainder of the
patients without high-risk criteria was assigned to the medium-risk group.
The study protocol was approved by the competent ethics committees
of the national coordinating centers (San Gerardo Hospital, Monza, Italy;
Hannover Medical School, Hannover, Germany; St Anna Children’s
Hospital, Vienna, Austria; and University Children’s Hospital, Zu¨rich,
Switzerland) and registered as clinical trials (ClinicalTrials.gov identiﬁers:
NCT00430118 [BFM] and NCT00613457 [AIEOP]). A data safety and
monitoring committee periodically supervised the study progress.
Randomization and Treatment
Only SR patients were eligible for random assignment. They were
assigned to receive either the experimental, less-intensive P-III or the
standard P-II as delayed intensiﬁcation. Random assignment was performed
P (log-rank) = .041
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Fig 3. (A) Disease-free survival (DFS), (B) cumulative incidence of relapse (CIR), and (C) overall survival (OS) in the as-treated analysis. HR, hazard ratio; pDFS, probability
of DFS; P-II, protocol II; P-III, protocol III.
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Sex
Male 
Female 
Age, years
 1 - ≤ 5
 6 - ≤ 9
 10
WBC (x 109/L)
< 20
20 - < 100 
> 100
Immunophenotype
Precursor B 
T 
ETV6-RUNX1
Negative 
Positive 
DNA index
 1.16
< 1.16 
Glucocorticoid
PDN
DXM
Total
293 (48.4)
291 (52.2)
361 (48.3)
127 (53.8)
96 (53.3)
405 (48.6)
151 (56.8)
28 (43.8)
554 (50.8)
25 (44.6)
353 (50.0)
188 (51.2)
91 (48.1)
349 (50.9)
251 (51.3)
268 (49.5)
584 (50.2)
312 (51.6)
267 (47.8)
386 (51.7)
109 (46.2)
84 (46.7)
428 (51.4)
115 (43.2)
36 (56.3)
537 (49.2)
31 (55.4)
353 (50.0)
179 (48.8)
98 (51.9)
337 (49.1)
238 (48.7)
273 (50.5)
579 (49.8)
0.1 1 10
89.9 (1.8)
93.7 (1.4)
93.8 (1.3)
92.1 (2.4)
81.6 (4.0)
93.2 (1.3)
90.0 (2.5)
82.1 (7.2)
91.8 (1.2)
92.0 (5.4)
89.6 (1.6)
95.1 (1.6)
93.4 (2.6)
90.5 (1.6)
93.5 (1.6)
90.5 (1.9)
91.8 (1.1)
87.2 (2.0)
97.0 (1.1)
95.3 (1.1)
98.2 (1.3)
90.3 (4.1)
96.0 (1.0)
94.7 (2.1)
97.1 (2.8)
96.2 (0.8)
93.2 (4.7)
94.8 (1.2)
97.7 (1.1)
95.2 (1.2)
96.1 (1.3)
94.3 (1.5)
95.8 (0.8)
94.8 (1.3)
91.2 (1.7)
91.2 (1.5)
89.4 (2.8)
81.6 (4.0)
91.3 (1.4)
85.9 (2.9)
78.0 (8.0)
89.4 (1.3)
81.2 (8.7)
86.2 (1.9)
94.5 (1.7)
97.9 (1.4) 90.0 (3.2)
89.4 (1.7)
90.5 (2.0)
87.9 (2.1)
89.2 (1.3)
91.6 (1.6)
Favors P-III Favors P-II
93.1 (1.6)
91.4 (1.5)
96.1 (1.9)
90.3 (4.1)
92.3 (1.4)
91.7 (2.6)
94.0 (4.1)
92.4 (1.2)
93.2 (4.7)
91.1 (1.6)
94.4 (1.8)
92.0 (2.9)
91.3 (1.6)
93.5 (1.7)
90.4 (1.9)
92.3 (1.2)
Sex
Male 
Female 
Age, years
 10
WBC (x 109/L)
< 20
20 - < 100 
> 100
Immunophenotype
Precursor B 
T 
ETV6-RUNX1
Negative 
Positive 
DNA index
 1.16
< 1.16 
Glucocorticoid
PDN
DXM
Total
293 (48.4)
291 (52.2)
361 (48.3)
127 (53.8)
96 (53.3)
405 (48.6)
151 (56.8)
28 (43.8)
554 (50.8)
25 (44.6)
353 (50.0)
188 (51.2)
91 (48.1)
349 (50.9)
251 (51.3)
268 (49.5)
584 (50.2)
312 (51.6)
267 (47.8)
386 (51.7)
109 (46.2)
84 (46.7)
428 (51.4)
115 (43.2)
36 (56.3)
537 (49.2)
31 (55.4)
353 (50.0)
179 (48.8)
98 (51.9)
337 (49.1)
238 (48.7)
273 (50.5)
579 (49.8)
9.4 (1.7)
3.1 (1.0)
4.8 (1.1)
6.3 (2.2)
14.1 (3.7)
5.1 (1.1)
8.0 (2.2)
14.3 (6.7)
6.2 (1.0)
8.0 (5.5)
8.4 (1.5)
2.7 (1.2)
4.4 (2.2)
7.5 (1.4)
3.7 (1.2)
8.2 (1.8)
6.3 (1.0)
4.2 (1.1)
1.9 (0.8)
3.9 (1.0)
1.8 (1.3)
6.1 (3.7)
2.6 (0.8)
5.3 (2.1)
2.9 (2.9)
2.6 (0.7)
6.8 (4.7)
3.7 (1.0)
1.7 (1.0)
1.0 (1.0)
3.6 (1.0)
3.0 (1.1)
4.5 (1.3)
3.2 (0.7)
11.6 (1.9)
5.7 (1.4)
7.4 (1.4)
8.0 (2.4)
14.1 (3.7)
6.9 (1.3)
12.1 (2.8)
14.3 (6.7)
8.6 (1.2)
12.6 (7.0)
11.4 (1.8)
3.3 (1.3)
7.8 (2.9)
8.6 (1.5)
6.1 (1.6)
10.9 (2.0)
8.7 (1.2)
7.4 (1.6)
5.2 (1.4)
7.4 (1.4)
3.9 (1.9)
6.1 (3.7)
5.9 (1.2)
8.3 (2.7)
6.0 (4.2)
6.6 (1.1)
6.8 (4.7)
7.5 (1.5)
4.3 (1.6)
7.0 (2.8)
7.0 (1.5)
5.7 (1.6)
7.9 (1.7)
6.4 (1.1)
0.1 1 10
Favors P-III Favors P-II
A
B
 1 - ≤ 5
 6 - ≤ 9
P-III P-II
4-Year 
pDFS % (SE)No.* (%) Hazard Ratio and 95% CI
8-Year 
pDFS % (SE)
P-III P-II P-III P-II
P-III P-II
4-Year 
CIR % (SE)No.* (%) Hazard Ratio and 95% CI
8-Year 
CIR % (SE)
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Fig 4. Forest plot of hazard ratio by patient subgroup for (A) disease-free survival (DFS), (B) cumulative incidence of relapse (CIR), and (C) overall survival (OS). (*) Data
refer to patients with successful investigation of the respective criteria. DXM, dexamethasone in induction treatment; pDFS, probability of DFS; PDN, prednisone in
induction treatment; P-II, protocol II; P-III, protocol III; pOS, probability of OS.
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centrally by each country’s data center in accordance with random permuted
blocks. This randomization was stratiﬁed by allocation to a preceding
random assignment (dexamethasone v prednisone) and treatment center.22
P-IIIwas shorter than P-II (duration, 28 v 49 days), and its cumulative
drug doses were reduced by 30% for dexamethasone and 50% for vin-
cristine, doxorubicin, and cyclophosphamide compared with P-II. An
outline of the SR treatment of AIEOP-BFM ALL 2000 is shown in Figure 1,
with drug doses also listed in the Data Supplement. P-II and P-III are split
into two parts. The ﬁrst part lasts from day 1 to 29 in P-II and from day 1 to
14 in P-III, whereas the second part lasts from days 36 to 49 in P-II and
from days 15 to 28 in P-III. Details on stratiﬁcation, prognostic impact of
MRD, and results of the random assignments during induction (dexa-
methasone 10 mg/m2/day v prednisone 60 mg/m2/day) have been pub-
lished previously.2,3,22 Criteria for cranial irradiation are listed in the Data
Supplement.
Statistical Analysis
The primary outcome was disease-free survival (DFS) because all
patients were in CR at random assignment. DFS was deﬁned as the time
from random assignment to the date of last follow-up or ﬁrst event. Events
were relapse, secondary neoplasm, or death from any cause. Secondary end
points were overall survival (OS) deﬁned as time to death from any cause,
or last follow-up, and treatment-associated toxicities.
The objective of this randomized trial was to prove noninferiority of
the reduced-intensity treatment compared with standard treatment. The
main analysis was planned as a per-protocol evaluation of 4-year DFS. All
randomly assigned patients were included in this analysis, but patients who
switched trial arms were included in the treatment arm actually given. In
addition, an intent-to-treat analysis was performed. The Kaplan-Meier
method was used to estimate survival probabilities; differences between
groups were compared by log-rank test.23 Cumulative incidence functions
for competing events were constructed by the method of Kalbﬂeisch and
Prentice and were compared with Gray’s test.24,25 The Cox proportional
hazard regression model was used for univariable and multivariable an-
alyses.26 A sample size of 1,024 randomly assigned patients was considered
appropriate to assess noninferiority (Δ , 4%) with 90% power under the
assumption of a 96% 4-year DFS in the reference arm. Two interim
analyses were planned 3 and 4 years after start of inclusion. For safety
reasons, the interim analysis was a log-rank test of difference instead of the
equivalence test planned for the ﬁnal analysis.
RESULTS
Patient Characteristics
From July 1, 2000, to June 30 (July 31 for AIEOP), 2006, 4,937
patients were enrolled in AIEOP-BFM ALL 2000, of whom 98 were
not eligible for evaluation (Fig 2). Among 1,346 SR patients eligible
for random assignment, 182 were not assigned. The remaining
1,164 patients entered the randomized comparison; 581 children
were allocated to the experimental arm P-III and 583 to the standard
arm P-II. We observed no signiﬁcant differences in initial patient
characteristics among randomly assigned versus nonrandomly assigned
patients as well as between the two arms analyzed by intention to
treat or treatment given (Data Supplemental).
Treatment Outcome
After a median follow-up of 8.6 years, analysis per treatment
given revealed a 4-year probability of DFS (pDFS 6 SE) rate of
293 (48.4)
291 (52.2)
361 (48.3)
127 (53.8)
96 (53.3)
405 (48.6)
151 (56.8)
28 (43.8)
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91.8 6 1.1% in the reduced-intensity P-III arm (n = 584) and of
95.8 6 0.8% in the P-II arm (n = 579; P = .04) on the basis of the
occurrence of 62 versus 42 events, respectively (Fig 3). The lower
limit of the one-sided 95% CI for the pDFS rates was 26.4%,
which is far below the noninferiority margin of24%, (P = .005 for
difference of the 4-year pDFS estimates). The respective results at
8 years were 89.26 1.3% and 92.36 1.2% for pDFS (P = .041) and
8.7 6 1.2% and 6.4 6 1.1% for cumulative incidence of relapse
(CIR; P-III v P-II, P = .09; Fig 3). The 8-year OS rate was 96.1 6
0.8% and 98.0 6 0.6% (P = .06). The intent-to-treat analysis gave
almost identical results (Data Supplement).
These differences of treatment outcome held for virtually all
clinical and biologic subgroups, although in many subgroups the
differences did not reach statistical signiﬁcance (Figs 4A to 4C).
ETV6-RUNX1 status and age at diagnosis represented the only
exception. Eight-year pDFS rates of patients with ETV6-RUNX1–
negative ALL were 86.26 1.9% versus 91.16 1.6% (P = .037) and
for patients with ETV6-RUNX1–positive ALL, 94.5 6 1.7% versus
94.46 1.8% (P = .74) for P-III versus P-II, respectively (Figs 5A and
5B). Analogous results held for age at diagnosis. For patients 1 to
10 years of age, the 8-year pDFS rate was 90.76 1.4% versus 92.46
1.2% (P = .26), and for patients age $ 10 years, 81.6 6 4.0%
versus 90.3 6 4.1% (P = .04) for P-III versus P-II, respectively
(Figs 5C and 5D).
The patterns of relapse with respect to time after diagnosis
were different after P-III and P-II. The proportion of early relapses
(ie, within 2.5 years after diagnosis) was higher in P-III than in P-II
(P-III, 19 [38.0%] of 50 relapses; P-II, 10 [28.6%] of 35 relapses);
the same occurred for late relapses (2.5 to , 5 years after di-
agnosis; P-III, 23 [46.0%] of 50 relapses; P-II, 10 [28.6%] of 35
relapses), but a signiﬁcantly higher proportion for very-late re-
lapse ($ 5 years after diagnosis) was observed in patients treated
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Fig 5. Disease-free survival (DFS) and cumulative incidence of relapse (CIR) according to ETV6-RUNX1 status and age at diagnosis (as treated). Data are shown for
probability of DFS (pDFS) for (A) patients with ETV6-RUNX1–negative and (B) ETV6-RUNX1–positive acute lymphoblastic leukemia, (C) patients 1 to 9 years of age and (D)
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leukemia, (G) patients 1 to 9 years of age and (H) patients $ 10 years of age. HR, hazard ratio; OS, overall survival; P-II, protocol II; P-III, protocol III.
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with P-II (P-III, eight [16.0%] of 50 relapses; P-II, 15 [42.9%] of
35 relapses; P[x2] = .022).
Secondary malignancies occurred in seven patients who
received P-III (myelodysplastic syndrome (n = 2); CNS tumor
(n = 2); acute myeloid leukemia (n = 2); and non-Hodgkin
lymphoma (n = 1) and in four patients who received P-II (mye-
lodysplastic syndrome (n = 2); acute myeloid leukemia (n = 1); and
solid tumor (n = 1). This ﬁnding corresponds to an 8-year cu-
mulative incidence rate of secondary malignancy of 1.36 0.5% and
0.6 6 0.4% for patients given P-III and P-II, respectively (P = .37;
Table 1).
An interaction between the initial corticosteroid in induction
and outcome after random assignment has not been observed
(Fig 4). Outcome by National Cancer Institute (NCI) criteria was
an 8-year pDFS rate of 91.66 1.4% versus 92.86 1.3% (P = .36),
a CIR rate of 7.0 6 1.3% versus 6.2 6 1.2% (P = .49), and an
8-year OS rate of 97.9 6 0.7% versus 98.1 6 0.7% (P = .77) for
NCI SR for P-III and P-II, respectively. For NCI high risk, the
8-year pDFS rate was 82.96 3.1% versus 90.46 2.7% (P = .041);
CIR rate, 13.06 2.8% versus 7.56 2.5% (P = .07); and 8-year OS
rate, 91.36 2.3% versus 97.76 1.3% (P = .021) for P-III and P-II,
respectively.
Toxicity
The incidence of death during remission was comparable,
with 0.9 6 0.4% (n = 5) and 0.7 6 0.3% (n = 4) for P-III and
P-II, respectively. The same applies for the number of adverse
events, which was essentially the same in the two arms (Table 2).
Life-threatening events, however, were slightly more likely to
happen with P-II (n = 10) than with P-III (n = 7).
If analyzed separately for the ﬁrst and the second phases of
P-II and P-III, life-threatening adverse events were mostly observed
in the ﬁrst phase of P-II, whereas patients treated with P-III
suffered from adverse events more frequently in the second phase
of P-III. The median time needed until start of the second part of
P-III or P-II was 15 days (n = 184 with data available) and 44 days
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(n = 173 with data available), respectively; 15 and 36 days were the
expected time according to protocol, respectively.
DISCUSSION
The attempt to reduce chemotherapy burden by choosing P-III as
a lower-intensity delayed intensiﬁcation in patients considered to
be at low relapse risk did not succeed because outcome results were
inferior to those obtained with the standard treatment. DFS data
showed a signiﬁcantly higher proportion of events in the exper-
imental arm, especially for patients who were ETV6-RUNX1
negative or $ 10 years of age. In addition, the expected beneﬁt of
reduced-intensity treatment in terms of acute toxicity and rates of
second malignancy could not be demonstrated. In fact, toxicity
seems to be virtually the same in both treatment arms. A possible
explanation for this observation is a less stringent handling of
patients in P-III by the treating physicians, which is probably
attributable to an underestimation of the impact of this treatment
element. This hypothesis is supported by the signiﬁcantly shorter
treatment delay between both parts of the respective treatment phase
(2 days in P-III v 14 days in P-II). Patients treated with P-III thus
experienced a higher dose density than patients treated with P-II.
Considering the higher number of relapses in patients treated
with the less-intensive P-III, at least a subpopulation in the SR
group was fairly undertreated with P-III. This refers particularly to
the inferior outcome of patients $ 10 years of age and those with
ETV6-RUNX1 negative precursor B-cell ALL, which suggests
a greater effect in subsets with known unfavorable characteristics
despite the very favorable early response depicted by highly sen-
sitive PCR-MRD.
In patients in the prognostically more favorable subgroups,
such as those with ETV6-RUNX1–positive ALL and those 1 to 6
years of age at diagnosis, the hazard ratios for the incidence of
relapse did not indicate an increase in the relapse rate, with the
disadvantage of treatment reduction possibly being negligible (Fig
4B). The same can be seen in patients treated with dexamethasone
during induction.
Table 1. Events
Event
Patient Group as Treated
P* HR (95% CI)
P-III (n = 584) P-II (n = 579)
No. (%)
4-Year Cumulative
Incidence, % (SE)
8-Year Cumulative
Incidence, % (SE) No. (%)
4-Year Cumulative
Incidence, % (SE)
8-Year Cumulative
Incidence, % (SE)
Death in ﬁrst CR 5 (0.9) 0.9 (0.4) 0.9 (0.4) 4 (0.7) 0.7 (0.3) 0.7 (0.3) .75 1.24 (0.33 to 4.63)
All relapses 50 (8.6) 6.3 (1.0) 8.7 (1.2) 35 (6.0) 3.2 (0.7) 6.4 (1.1) .09 1.45 (0.94 to 2.24)
Isolated BM 26 (4.5) 2.8 (0.7) 4.8 (0.9) 20 (3.5) 1.8 (0.6) 3.8 (0.8) .34 1.33 (0.74 to 2.38)
Isolated CNS 7 (1.2) 0.9 (0.4) 1.0 (0.4) 4 (0.7) 0.7 (0.3) 0.7 (0.3) .37 1.75 (0.51 to 5.97)
Isolated testes 5 (0.9) 0.9 (0.4) 0.9 (0.4) 2 (0.3) 0.4 (0.2) 0.4 (0.2) .27 2.54 (0.49 to 13.13)
Combined BM/CNS 6 (1.0) 0.7 (0.3) 0.9 (0.4) 4 (0.7) 0.4 (0.2) 0.6 (0.3) .52 1.52 (0.43 to 5.39)
Combined BM/other† 6 (1.0) 1.0 (0.4) 1.0 (0.4) 3 (0.5) 0.0 (0.0) 0.6 (0.3) .31 2.05 (0.51 to 8.21)
Other relapses‡ 0 (0.0) 0.0 (0.0) 0.0 (0.0) 2 (0.3) 0.0 (0.0) 0.4 (0.3) — —
Secondary neoplasms 7 (1.2) 1.0 (0.4) 1.3 (0.5) 4 (0.7) 0.4 (0.2) 0.6 (0.4) .37 1.76 (0.52 to 6.04)
Abbreviations: BM, bone marrow; CR, complete response; HR, hazard ratio; P-II, protocol II; P-III, protocol III.
*Fisher’s exact test was used for deaths and Gray’s test for relapses and secondary neoplasms.
†Other relapse sites comprise testis, eye, lymph node, and bone.
‡Other relapses comprise abdominal and ovary.
Table 2. Clinically Relevant Adverse Events Related to Delayed Intensiﬁcation Therapy
Adverse Events
Adverse Event, No. (%)*
Non–Life Threatening Life Threatening† Fatal
P-III‡ P-II‡ P-III‡ P-II‡ P-III‡ P-II‡
All 25 (4.2) 29 (5.0) 7 (1.2) 10 (1.7) 4 (0.7) 2 (0.4)
Infection related 8 (1.3) 9 (1.6) 4 (0.7) 5 (0.9) 3 (0.5) —
Not infection related 17 (2.9) 20 (3.5) 3 (0.5) 5 (0.9) 1 (0.2) 2 (0.4)
NOTE. All events are included that were related to therapy and occurred during or after delayed intensiﬁcation before the start of maintenance treatment. Events were
captured according to a list of clinically relevant events speciﬁed in the trial protocol. Infectious complications cover life-threatening infections, systemic/invasive fungal
infections, and severe local infections. Noninfectious events comprise pancreatitis, deep venous thrombosis, sinus venous thrombosis, cardiac insufﬁciency grade 3/4
and cardiac arrhythmias grade 3/4, seizures, alteration of consciousness grade 3/4, paresis/paresthesia, cerebral hemorrhage, cerebral stroke, severe psychosis that
requiresmedication, generalized exfoliative dermatitis, GI hemorrhage grade 3/4, GI ulcer grade 3/4, intestinal perforation, severe hepatic failure, veno-occlusive disease,
acute renal failure that requires dialysis, signiﬁcant chronic renal failure, drug-induced diabetes mellitus with hyperglycemic shock, allergic reaction with shock
symptoms, osteonecrosis, fracture, and other events assessed as clinically relevant by the investigators.
Abbreviations: P-II, protocol II; P-III, protocol III.
*Percentages are related to the total number of patients as treated in the respective arm (P-III, n = 584; P-II, n = 579).
†An adverse event was considered life threatening if its occurrence placed the patient at immediate risk of death. An adverse event that might have caused death, if it
had occurred in a more severe form, was not considered life threatening.
‡Patient group as treated.
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The current randomization was designed on the basis of the
results of the ALL-BFM 81 and ALL-BFM 83 trials, which were the
ﬁrst by our study group that introduced a reintensiﬁcation reg-
imen called protocol 3 in the SR groups. Furthermore, these two
trials documented the distinct importance of delayed in-
tensiﬁcation for the prevention of relapse.1,18,27 Hence, in sub-
sequent trials, reintensiﬁcation became an integral element of ALL
treatment by using the more intensive version of reintensiﬁcation
(P-II) from ALL-BFM 86.1,28 In the current trial (AIEOP-BFM
ALL 2000), P-III was randomized against the latter to ﬁnd an ap-
proximation toward a less-intensive, but still-effective treatment.
Most recently, the Dutch Childhood Oncology Group (DCOG)
reported the results of its study DCOG ALL10 with nonrandomized
treatment reduction for SR patients during delayed intensiﬁcation.11
The risk stratiﬁcation criteria in this trial were similar to those in our
trial. Treatment of SR patients was also comparable except for the
reduced delayed intensiﬁcation phase, which was considerably more
reduced in intensity in that trial than in P-III. With reduced-intensity
chemotherapy at a median follow-up of 80 months, 194 patients had
a 5-year pEFS rate of 93.16 1.9% and 5-year CIR rate of 6.46 1.85%.
The outcome results in this rather small cohort were interpreted as
improvement compared with historical controls of the DCOG, and
therapy reduction was declared as safe by study criteria. However, the
pEFS was inferior, although not signiﬁcant, to the results of the
historicalMRD-SR group as reported by the International BFM Study
Group5 (5-year pEFS, 98%; SE, 2%; n = 55; P = .08).
Of note, the rates of 5-year pEFS and 5-year CIR in the DCOG
study were in between the respective results of P-III (5-year pDFS,
90.66 1.2% [D = 2.5%]; 5-year CIR, 7.56 1.1% [D = 1.1%]) and
P-II (5-year pDFS, 94.9 6 0.9% [D = 1.8%]; 5-year CIR, 4.1 6
0.8% [D =22.3%]) of the AIEOP-BFMALL 2000 trial. This ﬁnding
leaves open the question of whether the reduced intensity in the
DCOG study is really noninferior to standard treatment with P-II.
In the study Malaysia-Singapore ALL 2003 s, risk stratiﬁcation
was likewise based on PCR-MRD by basically using the same risk
stratiﬁcation criteria as in our and the DCOG ALL10 protocols.
SR patients were treated with a nonrandomized reduced therapy on
the backbone of the ALL-Intercontinental BFM 2002 protocol.13,29
The treatment included a three-drug induction without anthracy-
clines as well as a reduced reinduction roughly comparable to P-III as
reported here. With a rather short median follow-up of 3.38 years,
the SR group of 172 patients had a 6-year pEFS rate of 93.26 4.1%
and a 6-year OS rate of 95.4 6 3.3%, which depicts major im-
provement with the reduced-intensity treatment approach com-
pared with preceding results of this study group along with a lower
incidence of fatal and/or life-threatening treatment-related events.
With the lack of a randomized approach, however, these im-
provements hardly could be differentiated from general improve-
ments in quality of treatment and supportive care.
A randomized approach was chosen in the protocol of the
British study group trial UKALL 2003, where 521 low-risk patients
assessed by NCI criteria and PCR-MRD were randomly assigned to
receive either one or two delayed intensiﬁcation courses.12 With
a median follow-up of 57 months, a difference in 5-year pEFS rate
of 1.1%was reported (94.4% v 95.5%). The 95%CI of the difference
was 25.6% to 2.5%. The authors concluded that the primary end
point of the randomization (to rule out a 7% reduction in EFS) was
achieved. With the noninferiority margin of 4% in the current trial,
this would not be true. Deﬁning a reasonable noninferiority margin
is always a matter of debate.
Another randomized treatment question about delayed in-
tensiﬁcation was asked by the US Children’s Oncology Group.
Comparability with the aforementioned trials and our study,
however, is even more limited because MRD was not used for risk
stratiﬁcation.10 The authors demonstrated that the addition of
a second delayed intensiﬁcation in the treatment schedule of NCI
SR patients with rapid early cytologic marrow response did not
offer an advantage in terms of 5-year pEFS and OS rate (90.9 6
1.3% and 97.1 6 0.8% v 90.5 6 1.3% and 95.4 6 3.8% for single
and double delayed intensiﬁcation, respectively).
In summary, both of the latter-cited trials—UKALL 2003 and
COG 1991—revealed the feasibility of treatment reduction in patients
with the most favorable prognosis in a randomized approach. Dis-
crepancies with the results presented heremight be explained by a fairly
different treatment approach. A higher treatment intensity in the re-
duced intensity arm with single delayed intensiﬁcation, which is
comparable with P-II in the current study, presumably is a critical
threshold that has not been reached. Differences in the risk stratiﬁcation
approaches also hamper comparability with the current trial.11,13,28
As a future perspective, a constant reﬁning of biologic subtypes
and treatment response is warranted to ensure the best possible
treatment stratiﬁcation throughout study groups. Insertion of novel
drugs in chemotherapeutic regimens and implementation of targeted
therapies, such as leukemia-speciﬁc antibodies, hopefully will take
their place in the treatment of SR leukemia and thus enable a re-
duction of conventional drugs. In particular, by sparing anthracyclines
and alkylating agents, the reduction of acute and long-term toxicity
could be achieved. However, as the results of the presented trial
demonstrate, future development should be implemented carefully by
means of randomized trials designed to recruit sufﬁciently large
cohorts to enable detection of clinically relevant differences.
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